Experience with selexipag in triple therapy for pulmonary arterial hypertension in Chinese children
Abstract Background Selexipag is an orally effective prostacyclin receptor agonist that has been approved for treating pulmonary arterial hypertension (PAH) in adults but is still used off-label in children. This study aimed to evaluate the efficacy and safety of selexipag as part of triple combinat...
Salvato in:
| Autori principali: | , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMC
2026-05-01
|
| Serie: | BMC Pediatrics |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1186/s12887-026-06954-9 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|